Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treg/Tcon Adoptive Immunotherapy in Allogeneic HSCT
NCT03977103Phase 2Unknown
- Sponsor
- University of Perugia
- Start
- Feb 2014
- Primary completion
- Feb 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Treg/Tcon adoptive immunotherapy in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin lymphoma (NHL), sponsored by University of Perugia. Status: unknown.
02
Drugs
Treg/Tcon adoptive immunotherapy
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03977103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977103.